Anzeige
Mehr »
Login
Sonntag, 12.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 935256 | ISIN: FR0004044600 | Ticker-Symbol: RFX
Stuttgart
10.01.25
12:56 Uhr
5,300 Euro
0,000
0,00 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
PRISMAFLEX INTERNATIONAL SA Chart 1 Jahr
5-Tage-Chart
PRISMAFLEX INTERNATIONAL SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,4005,85011.01.
Actusnews Wire
666 Leser
Artikel bewerten:
(2)

PRISMAFLEX INTERNATIONAL: Strong 2024-2025 half-year results

Finanznachrichten News

Lyon, December 11, 2024

Positive results maintained

Continued reduction of net debt

Large increase in order backlog


2024-2025 six-month period analysis

  • Total sales down just 3.1%. Printing activity remains strong (-1%) while Hardware activity is down 8% before an anticipated upturn in S2.
  • Current EBITDA almost stable at €2.2 million (8.4% of total sales) reflecting the Group's good control of operating expenses.
  • Positive net result at €0.7 million.
  • Positive €1.4 million free cash flow allowing to pursue the reduction of net debt.
  • Order backlog on September 30, 2024 significantly up at €13.8 million (vs €8.2 million one year ago), offering a positive outlook for S2.


Six-month results (01/04/2024 - 30/09/2024)

The 2024-2025 six-month consolidated results were subject to a limited review by the Statutory Auditors and were approved by the Prismaflex International Board on December 5, 2024.

In €M
30.09.24
6 months
30.09.23
6 months

Var (€M)
Total sales25.826..6-0.8
Gross margin113.313.0+0.3
Gross margin rate51.6%48.9%
Current EBITDA22.22.3-0.1
Current EBITDA rate8.4%8.6%
Current operating profit1.01.0=
Operating profit1.01.1-0.1
Financial result(0.2)(0.2)
Current earnings before tax0.80.9-0.1
Tax(0.1)(0.2)
Net result0.70.7=
Net consolidated result - Group0.60.6=

1 Total sales - consumables purchased, sub-contracting, installation, purchase and sales transport costs

2 Current operating profit + net depreciation expense and provisions + other calculated income and charges


S1 2024-2025 results confirm the Group's resilience in a challenging economic climate. Despite a slight drop in activity, Prismaflex International records stable and positive results for the six-month period compared with S1 2023-2024, while continuing the reduction of net debt.

Total sales for the period stand at €25.8 million, close to figures recorded in S1 2023-2024 (-€0.8 million). A dynamic business activity led to a growth in order backlog towards the end of the period.

Printing activity recorded total sales for the period of €18.7 million, on a par with the figures recorded for S1 2023-2024 (-1.0%). Communications activity is going strong (€18.1 million / +€1.3 million) to represent over 96% of total sales for the division. This performance makes up for the significant fall in Home Décor activity (€0.6 million / -€1.5 million) on what continues to be a sluggish market.

Hardware activity stands at €7.2 million, down €0.6 million on S1 2023-2024. A drop in LED activity due to the absence of significant deliveries was made up for by major deliveries of street furniture and increasing interest in new advertising solutions for the retail sector.

Gross margin rate is up 2.9 points at 51.6%, thanks to a favourable product mix, notably concerning Hardware and the careful control of supply costs.

This improvement in gross margin rate allowed to absorb the slight increase in operating expenses, notably personnel expenses and other external costs following an increase in use of temporary staff. Current EBITDA stand at €2.2 million, or 8.4% of total sales revenue.

After net depreciation expense and provisions, current operating profit stands at €1.0 million. In the absence of any significant noncurrent elements, operating profit is also at €1.0 million.

Current earnings before tax stands at €0.8 million, with financial interest on debt of €0.2 million.

Net result is also stable at €0.7 million.


Financial situation: debt pay-off continues

30.09.2431.03.24
Equity shareholders (including minority shareholders)9.79.1
Net debt9.810.9
Gearing101%120%
Net debt (before IFRS 16)8.08.7
Gearing (before IFRS 16)83%96%

Cash flow generated by the activity stands at €1.6 million, and includes a self-financing capacity of €2.2 million (before interest and tax) and an increase in working capital of €0.4 million following an increase in stocks to satisfy the growth in order backlog.

Production-related investments were limited to only €0.2 million over the period. Free cash-flow for the period stands at €1.4 million and was used for debt reduction and debt-servicing purposes.

Net debt, including €2.2 million IFRS 16-related debt release, is down at €9.8 million (€8.0 million before IFRS 16) vs €10.9 million (€8.7 million before IFRS 16) on March 31, 2024. Gearing is therefore down at 1.01 (0.83 before IFRS 16) and cash available stands at €3.1 million (vs €3.3 million on March 31, 2024).


Outlook 2024-2025

Prismaflex International begins S2 with order backlog at €13.8 million, much higher than on September 30, 2023 (€8.2 million), offering a very encouraging outlook for S2 that should confirm the Group's profitable growth trajectory.

The Hardware division will return to growth thanks to a solid order backlog at €9.3 million, up more than €5 million on September 2023, thanks to a high level of orders for LED solutions for the French municipalities sector and an increase in deliveries of hardware solutions for the retail sector. Street furniture activity is also buoyant in both France and Germany.

The Printing division should perform as in S1, with a dynamic Communications sector in all the countries the Group operates in.

In such a context, Prismaflex International aims to achieve a return to growth, to improve operating profitability and to continue the reduction of net debt.


Publication of the half-year report as at 30 September 2024

The half-year 2024/25 report of Prismaflex International is available on the "Financial Information" page of the company's website at www.prismaflex.com and on the wire's website at www.actusnews.com.



Forthcoming dates

Half-year results presentation videoconference, on December 12, 2024 at 11.30am

Press release

Q3 2024-2025 results, January 23, 2025 after closure

PRISMAFLEX INTERNATIONAL
OUTDOOR ADVERTISING SOLUTIONS MANUFACTURER AND WIDE FORMAT DIGITAL PRINTING
ISIN: FR0004044600-ALPRI - Reuters: ALPRI.PA - Bloomberg: ALPRI.FP
EURONEXT GROWTHTM

www.prismaflex.com

Contacts :

Florence Thérond - CFO - Phone: +33 (0)4 74 70 68 00 - finance@prismaflex.com

Guillaume Le Floch - Analysts/investors contacts - Phone: +33 (0)1 53 67 36 70 - glefloch@actus.fr

Marie-Claude Triquet - Press relations - Phone: +33 (0)6 84 83 21 82 - mctriquet@actus.fr

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: xm1wlJttlWnHnJpwYZ1tmWlonG9jlGmdl5ecxmhsZ57FnG5pnJiVbsqeZnFqlmVr
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-89105-pri-111223-rs-24-25-gb.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2024 Actusnews Wire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.